Tumor BRCA Testing in High Grade Serous Carcinoma: Mutation Rates and Optimal Tissue Requirements

SIMPLE SUMMARY: Approximately 25% of women diagnosed with tubo-ovarian high-grade serous carcinoma have germline deleterious mutations in BRCA1 or BRCA2, characteristic of hereditary breast and ovarian cancer syndrome, while somatic mutations have been detected in 3–7%. We set out to determine the m...

Descripción completa

Detalles Bibliográficos
Autores principales: Turashvili, Gulisa, Lazaro, Conxi, Ying, Shengjie, Charames, George, Wong, Andrew, Hamilton, Krista, Yee, Denise, Agro, Evangeline, Chang, Martin, Pollett, Aaron, Lerner-Ellis, Jordan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7700467/
https://www.ncbi.nlm.nih.gov/pubmed/33233347
http://dx.doi.org/10.3390/cancers12113468

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7700467/
https://www.ncbi.nlm.nih.gov/pubmed/33233347
http://dx.doi.org/10.3390/cancers12113468

Ejemplares similares